Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Genentech, a member of the Roche Group, today announced results from OCEANS, a Phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy followed by the continued use of Avastin alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.

6 Jun 2011

ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced positive clinical data with the Company's IMGN901 (lorvotuzumab mertansine) product candidate as featured in an oral presentation at the ASCO 2011 Annual Meeting in Chicago.

6 Jun 2011

Women with ovarian cancer do not benefit from CA-125 and transvaginal ultrasound

In a clinical trial that included nearly 80,000 women, those who received ovarian cancer screening did not have a reduced risk of death from ovarian cancer compared to women who received usual care, but did have an increase in invasive medical procedures and associated harms as a result of being screened, according to a study in the June 8 issue of JAMA, a theme issue on cancer.

6 Jun 2011

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.

6 Jun 2011

Screening unhelpful in lowering deaths from ovarian cancer

New research shows that women regularly screened for ovarian cancer are just as likely to die from the disease. This comes as no surprise as there are still no adequate detection methods, says Ovarian Cancer Australia. Of the 1,200 Australian women diagnosed with ovarian cancer each year, 800 die, often because it is diagnosed too late to be treated.

5 Jun 2011

Scientists find way to protect kidney from cancer drug toxicity

Scientists may have a way to make the powerful cancer drug cisplatin less toxic to the kidneys and more effective against some cancers.

4 Jun 2011

HRT reduces risk of breast cancer in women with BRCA mutations after ovary removal

Women with the BRCA1 or BRCA2 gene mutations, which are linked to a very high risk of breast and ovarian cancer, can safely take hormone-replacement therapy (HRT) to mitigate menopausal symptoms after surgical removal of their ovaries, according to new research from the Perelman School of Medicine at the University of Pennsylvania which will be presented Monday, June 6 during the American Society for Clinical Oncology's annual meeting.

4 Jun 2011

EntreMed's ENMD-2076 Phase 2 trial data on platinum-resistant ovarian cancer presented at ASCO 2011

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced the presentation of clinical data for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients.

4 Jun 2011

ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011

Data related to ZYTIGA (abiraterone acetate) will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

3 Jun 2011

Octomom’s fertility specialist loses license

A Beverly Hills fertility doctor who assisted Nadya Suleman in conceiving octuplets is set to lose his medical license, the Medical Board of California announced Wednesday.

2 Jun 2011

Women with ovarian cancer could benefit from new targeted testing

Women with ovarian cancer could be helped by a new test that identifies the specific type of tumour they have, a conference will hear this week.

1 Jun 2011

Almac's main research projects on ovarian, breast cancer to be presented at ASCO 2011

Two of Almac's main research projects have been selected for presentation at the 2011 ASCO meeting. Both of these studies are based on Almac's approach of profiling large clinical datasets and analysing the data for molecular subgroups that can aid in improved diagnosis of cancer by identifying molecular subtypes and by identifying molecular subgroups which are of clinical and therapeutic relevance.

31 May 2011

Canadian women more aware of ovarian cancer now, but misconceptions remain

Canadian women know more about ovarian cancer than they did six years ago, but misconceptions remain that could lead to late diagnosis of the country's most fatal gynecologic cancer - a disease that claims the lives of 70% of those diagnosed.

30 May 2011

New insights into pathogenesis and treatment of hereditary breast, ovarian cancer

5% to 10% of all breast cancers are monogenic in origin. In other words, there is a mutation of the genes BRCA1, BRCA2 or other high-risk genes. In this edition of Deutsches Ärzteblatt International, Alfons Meindl of the Klinikum rechts der Isar and coauthors report on new insights into the pathogenesis and treatment of hereditary breast and ovarian cancer and newly-discovered risk genes.

30 May 2011

OVA1 more effective than CA 125 test in evaluating likelihood of ovarian cancer

A paper published in the June issue of Obstetrics & Gynecology demonstrated that adding OVA1 to a physician's preoperative assessment of a woman's ovarian mass would identify more ovarian cancers than a physician's preoperative assessment alone.

From Quest Diagnostics 27 May 2011

ImmunoGen's clinical data on IMGN901 and SAR3419 to be presented at ASCO 2011

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that favorable clinical data on two ImmunoGen-created TAP compounds - IMGN901 and SAR3419 - are being presented at the ASCO 2011 Annual Meeting taking place in Chicago, IL, June 4-8, 2011.

26 May 2011

NWBT accelerates addition of clinical sites for new enrollment into ongoing GBM brain cancer trial

Northwest Biotherapeutics today announced that it has accelerated the addition of clinical trial sites, exceeding its projections for the doubling of such sites across the U.S. this calendar quarter, for enrollment of new patients into the Company's ongoing 240-patient randomized, double blind, placebo controlled clinical trial of DCVax immune therapy for Glioblastoma multiforme, the most lethal form of brain cancer.

26 May 2011

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

A study titled "Abiraterone and Increased Survival in Metastatic Prostate Cancer," published in the May 26 issue of NEJM, found that patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel showed a significant improvement in overall survival when treated with ZYTIGA plus prednisone compared to patients treated with prednisone plus placebo.

26 May 2011

Variant of obesity gene may increase breast cancer risk

New research aimed to better identify the genetic factors that lead to breast cancer has uncovered a link between the fat mass and obesity associated gene and a higher incidence of breast cancer.

24 May 2011

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

Exelixis, Inc. today announced the results of the phase 1 clinical trial of cabozantinib in patients with advanced solid tumors or lymphoma have been published in the current issue of the Journal of Clinical Oncology.

24 May 2011

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011

Women with ovarian cancer do not benefit from CA-125 and transvaginal ultrasound

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Screening unhelpful in lowering deaths from ovarian cancer

Scientists find way to protect kidney from cancer drug toxicity

HRT reduces risk of breast cancer in women with BRCA mutations after ovary removal

EntreMed's ENMD-2076 Phase 2 trial data on platinum-resistant ovarian cancer presented at ASCO 2011

ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011

Octomom’s fertility specialist loses license

Women with ovarian cancer could benefit from new targeted testing

Almac's main research projects on ovarian, breast cancer to be presented at ASCO 2011

Canadian women more aware of ovarian cancer now, but misconceptions remain

New insights into pathogenesis and treatment of hereditary breast, ovarian cancer

OVA1 more effective than CA 125 test in evaluating likelihood of ovarian cancer

ImmunoGen's clinical data on IMGN901 and SAR3419 to be presented at ASCO 2011

NWBT accelerates addition of clinical sites for new enrollment into ongoing GBM brain cancer trial

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

Variant of obesity gene may increase breast cancer risk

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in